Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure
M Mack, WH Frishman - Cardiology in Review, 2024 - journals.lww.com
Systolic Heart failure is a complex clinical syndrome characterized by a decrease in cardiac
contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to …
contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to …
Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure.
M Mack, WH Frishman - Cardiology in Review, 2023 - europepmc.org
Systolic Heart failure is a complex clinical syndrome characterized by a decrease in cardiac
contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to …
contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to …
Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure
M Mack, WH Frishman - Cardiology in Review - journals.lww.com
Systolic Heart failure is a complex clinical syndrome characterized by a decrease in cardiac
contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to …
contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to …
Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure
M Mack, WH Frishman - Cardiology in review - pubmed.ncbi.nlm.nih.gov
Systolic Heart failure is a complex clinical syndrome characterized by a decrease in cardiac
contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to …
contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to …